Target Name: IL1RAPL1
NCBI ID: G11141
Other Name(s): IL-1RAPL-1 | IL1RAPL-1 | OPHN4 | IL1RAPL | X-linked interleukin-1 receptor accessory protein-like 1 | three immunoglobulin domain-containing IL-1 receptor-related 2 | Oligophrenin-4 | Interleukin-1 receptor accessory protein-like 1 | MRX10 | Interleukin 1 receptor accessory protein like 1 | Interleukin 1 receptor-8 | IL-1-RAPL-1 | mental retardation, X-linked 10 | Three immunoglobulin domain-containing IL-1 receptor-related 2 | interleukin 1 receptor accessory protein like 1 | IRPL1_HUMAN | interleukin 1 receptor-8 | oligophrenin-4 | Mental retardation, X-linked 21 | MRX21 | MRX34 | Mental retardation, X-linked 34 | TIGIRR-2 | IL1R8

IL-1RAPL-1: A Potential Drug Target and Biomarker

The immune system is a crucial part of our bodies, and it plays a vital role in protecting us from harmful pathogens and diseases. One of the key proteins involved in this system is IL-1RAPL-1, which is a cytokine that is expressed in various tissues and cells throughout the body. In recent years, researchers have become increasingly interested in IL-1RAPL-1 as a potential drug target and biomarker, which could lead to new treatments for a range of diseases.

IL-1RAPL-1 is a 14-kDa cytokine that is produced by various cell types in response to an infection or injury. It is a key mediator of the inflammatory response, and it has been shown to play a role in the development of a variety of diseases, including cancer, autoimmune disorders, and neuroinflammatory diseases.

One of the key functions of IL-1RAPL-1 is its role in the regulation of pain. IL-1RAPL-1 has been shown to play a key role in the development of chronic pain in various organisms, including mammals. For example, studies have shown that IL-1RAPL-1 is involved in the regulation of pain perception and neuroinflammation, and that it can contribute to the development of pain-related diseases.

In addition to its role in pain regulation, IL-1RAPL-1 has also been shown to be involved in the development of other diseases. For example, it has been linked to the development of cancer, neuroinflammatory diseases, and autoimmune disorders.

As a potential drug target, IL-1RAPL-1 has the potential to be used to treat a wide range of diseases. For example, it has been shown to be involved in the regulation of cancer cell growth and metastasis, and it has been shown to have anti-inflammatory effects that could make it a useful treatment for neuroinflammatory diseases. Additionally, IL-1RAPL-1 has been shown to play a key role in the regulation of pain, and has been shown to have analgesic effects in various organisms.

As a biomarker, IL-1RAPL-1 has the potential to be used as a diagnostic tool for a wide range of diseases. For example, it has been shown to be involved in the regulation of pain, and its levels have been associated with the severity of pain in various organisms. Additionally, IL-1RAPL-1 has been shown to be involved in the regulation of inflammation, and its levels have been associated with the level of inflammation in various organisms.

In conclusion, IL-1RAPL-1 is a protein that is involved in various aspects of the immune system and has the potential to be used as a drug target and biomarker in a wide range of diseases. Further research is needed to fully understand the role of IL-1RAPL-1 in these systems and to develop new treatments based on its properties.

Protein Name: Interleukin 1 Receptor Accessory Protein Like 1

Functions: May regulate secretion and presynaptic differentiation through inhibition of the activity of N-type voltage-gated calcium channel (PubMed:12783849). May activate the MAP kinase JNK (PubMed:15123616). Plays a role in neurite outgrowth (By similarity). During dendritic spine formation can bidirectionally induce pre- and post-synaptic differentiation of neurons by trans-synaptically binding to PTPRD (By similarity)

More Common Targets

IL1RAPL2 | IL1RL1 | IL1RL2 | IL1RN | IL2 | IL20 | IL20RA | IL20RB | IL21 | IL21-AS1 | IL21R | IL21R-AS1 | IL22 | IL22RA1 | IL22RA2 | IL23A | IL23R | IL24 | IL25 | IL26 | IL27 | IL27RA | IL2RA | IL2RB | IL2RG | IL3 | IL31 | IL31RA | IL32 | IL33 | IL34 | IL36A | IL36B | IL36G | IL36RN | IL37 | IL3RA | IL4 | IL4I1 | IL4R | IL5 | IL5RA | IL6 | IL6-AS1 | IL6R | IL6R-AS1 | IL6ST | IL6ST-DT | IL6STP1 | IL7 | IL7R | IL9 | IL9R | IL9RP3 | IL9RP4 | ILDR1 | ILDR2 | ILF2 | ILF3 | ILF3-DT | ILK | ILKAP | ILRUN | ILVBL | Imidazoline I2 receptor (I2) | Imidazoline I3 receptor (I3) | Imidazoline receptor | IMMP1L | IMMP2L | IMMT | IMMTP1 | Immunoglobulin A | Immunoglobulin E (IgE) | Immunoglobulin G | Immunoglobulin M | Immunoglobulin-Like Domain Containing Receptor | Immunoproteasome | IMP3 | IMP4 | IMPA1 | IMPA1P1 | IMPA2 | IMPACT | IMPDH1 | IMPDH1P10 | IMPDH1P6 | IMPDH2 | IMPG1 | IMPG2 | INA | INAFM1 | INAFM2 | INAVA | INCA1 | INCENP | INE1 | INE2 | INF2 | ING1 | ING2